Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
ST. LOUIS, July 20, 2011 /PRNewswire/ -- Beginning July 29, Mark J.
Researchers from Mount Sinai School of Medicine will present several key studies at the American Academy of Neurology (AAN) annual meeting, including research providing critical insight into the prognosis and clinical treatment course of people with a certain subtype of Multiple Sclerosis (MS).
PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
EAST HANOVER, N.J., Sept.
Adding albuterol, a compound commonly used to treat asthma and other respiratory diseases, to an existing treatment for patients with multiple sclerosis appears to improve clinical outcomes.
EXTON, Pa., June 2 /PRNewswire/ -- BioTrends released the first wave of LaunchTrendsÂ®: New Products in Multiple Sclerosis (MS), a three wave syndicated report series designed to track the uptake of Novartis's Extavia and Acorda's Ampyra.
EXTON, Pa., April 26 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis.
- totally perplexed and mixed up.